MAGE-A4ᶜ¹º³²T for Multi-Tumor

Inclusion Criteria:

Subject is ≥18 to 75 years of age at the time of signing the study informed consent.
Subject has histologically confirmed diagnosis of any one of the indicated tumor types
Subject is HLA-A*02 positive. (This determination will be made under screening protocol ADP-0000-001).
Subject's tumor shows expression of the MAGE-A4 RNA or protein. (This determination will be made under screening protocol ADP-0000-001).
Adequate organ function as indicated in the study protocol
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion
Subject meets disease-specific requirements per protocol

7. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.

Exclusion Criteria:

Subject does not express appropriate HLA-A genotype
Subject is receiving excluded therapy/treatment per protocol
Subject has symptomatic CNS metastases.
Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness.
Subject has active infection with HIV, HBV, HCV or HTLV
Subject is pregnant or breastfeeding.

Additional Exclusion Criteria for the Radiation Substudy:

Subject does not meet eligibility criteria for the main study (ADP-0044-001).
Subject does not have at least one target lesion amenable to radiation.
Certain radiation therapy within 6 months of clinical trial are an exclusion.
Metastatic disease impinging on the spinal cord or threatening spinal cord compression.